Chemotherapy News and Research

Latest Chemotherapy News and Research

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

A Novartis Pharmaceuticals Corporation Phase III study of Afinitor® (everolimus) tablets in combination with Sandostatin® LAR Depot (octreotide acetate for injectable suspension) extended median progression-free survival (PFS), or time without tumor growth, in patients with advanced carcinoid tumors compared to taking octreotide LAR alone.

11 Oct 2010

New natural dietary components inhibit breast cancer cells

Researchers at Indiana University and Methodist Research Institute have published the dramatic effects of a natural formula against breast cancer. The impressive results are found in the most recent publication of Integrative Cancer Therapies. Lead investigator Dr. Daniel Sliva says, The formula we studied inhibits growth of highly metastatic human breast cancer cells, and suppresses metastatic potential of these cells.

11 Oct 2010

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics, Inc. and Millennium The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced positive top-line results from a phase II clinical trial of single-agent brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC) targeted to CD30. The trial was conducted in 58 relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) patients.

11 Oct 2010

Seattle Genetics reports SGN-75 phase I clinical trial data

Seattle Genetics, Inc. today reported data from a phase I clinical trial of SGN-75 in patients with non-Hodgkin lymphoma or renal cell carcinoma (RCC). Preliminary results demonstrate tolerability and antitumor activity, including two objective responses in the first 16 patients treated. Dose-escalation is continuing.

11 Oct 2010

Researchers identify factor that affects breast cancer patients' survival time in chemotherapy

In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.

11 Oct 2010

Phase-II clinical trial of MLN8237 drug shows promising results for treating ovarian cancer

A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.

11 Oct 2010

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Research may offer new therapy targets for drug-resistant breast tumors

Researchers at the University of Illinois at Chicago College of Medicine have found how gene expression that may contribute to drug resistance is ramped up in unusual types of breast tumors. Their findings may offer new therapy targets.

11 Oct 2010

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

A new type of breast cancer treatment has shown encouraging activity as a first-line therapy in HER2-positive metastatic disease, researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010

Novel peptide NX002 demonstrates efficacy in animal model of oral mucositis: Study

NephRx Corporation today announced that a new study has shown that its novel peptide NX002 demonstrated significant efficacy when tested in an animal model of oral mucositis. Mucositis is a debilitating and often dose-limiting side effect of many forms of cancer therapy that affects more than 400,000 patients who receive chemotherapy or radiation treatment in the U.S. each year. Current treatment options are very limited.

8 Oct 2010

AngioDynamics reports 3% increase in net sales for fiscal 2011 first quarter

AngioDynamics, a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, today reported financial results for the fiscal 2011 first quarter ended August 31, 2010 that were in line with the preliminary results reported on September 7, 2010.

7 Oct 2010

Role of TGF-ß in cancer diseases

During this year's BIOTECHNICA exhibition, the international biotech news magazine „GEN - Genetic Engineering & Biotechnology News yesterday on 5 October 2010, held an information event with subsequent panel discussion featuring the topic TGF-ß an important target in cancer diseases.

7 Oct 2010

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology.

7 Oct 2010

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.

7 Oct 2010

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

The Focused Ultrasound Surgery Foundation is hosting the 2nd International Symposium on MR-guided Focused Ultrasound in Chantilly, Virginia from October 17-20. Leading researchers and clinicians from around the world will gather at the three-day scientific conference to present and discuss the latest advancements in one of the most revolutionary and promising areas of therapeutic medicine.

6 Oct 2010

Amgen to present oncology portfolio results at ESMO Congress

Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.

6 Oct 2010

CTTC, Spero enter sales agreement for Calmare medical devices

Competitive Technologies, Inc. announced today that it has entered into a sales agreement with Spero Pain Relief Therapy, LLC. Spero, based in St. George, UT, opened its first of 14 planned pain clinics using CTTC's Calmare Pain Therapy medical device last month.

6 Oct 2010

Lixte, NCI collaborate for clinical evaluation of LB-100 compound

Lixte Biotechnology Holdings announced today that the National Cancer Institute Experimental Therapeutics (NExT) Program Senior Advisory Committee (SAC), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), signed a NExT Material Transfer Agreement formalizing a collaboration with Lixte Biotechnology Holdings, Inc. for clinical evaluation of LB-100, one of Lixte's lead anti-cancer compounds.

6 Oct 2010

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

The Coalition for Pulmonary Fibrosis (CPF) has announced its annual awards honoring three critical areas of leadership that impact the work of the Pulmonary Fibrosis (PF) community.

5 Oct 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Afinitor-Sandostatin LAR Depot combination extends median PFS in patients with advanced carcinoid tumors

New natural dietary components inhibit breast cancer cells

Millennium, Seattle Genetics announce positive top-line results of SGN-35 phase II clinical trial

Seattle Genetics reports SGN-75 phase I clinical trial data

Researchers identify factor that affects breast cancer patients' survival time in chemotherapy

Phase-II clinical trial of MLN8237 drug shows promising results for treating ovarian cancer

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

Research may offer new therapy targets for drug-resistant breast tumors

Anti-HER2 antibody-drug conjugate effective as first-line therapy for advanced breast cancer: Research

Abiraterone Phase III clinical data to be presented at ESMO meeting

Novel peptide NX002 demonstrates efficacy in animal model of oral mucositis: Study

AngioDynamics reports 3% increase in net sales for fiscal 2011 first quarter

Role of TGF-ß in cancer diseases

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

Focused Ultrasound Surgery Foundation hosts conference to discuss advancements in therapeutic medicine

Amgen to present oncology portfolio results at ESMO Congress

CTTC, Spero enter sales agreement for Calmare medical devices

Lixte, NCI collaborate for clinical evaluation of LB-100 compound

CPF honors three critical areas of leadership for Pulmonary Fibrosis community

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Newsletters you may be interested in